SS
RARE icon

SBI Securities’s Ultragenyx Pharmaceutical RARE Stock Holding History

SBI Securities’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.44K Sell
133
-70
-34% -$1.74K ﹤0.01% 2226
2026
Q1 		$4.25K Buy
203
+29
+17% +$653 ﹤0.01% 2102
2025
Q4 		$4K Buy
174
+140
+412% +$4.6K ﹤0.01% 2109
2025
Q3 		$1.02K Buy
34
+19
+127% +$570 ﹤0.01% 2686
2025
Q2 		$545 Hold
15
– – ﹤0.01% 2932
2025
Q1 		$543 Buy
15
+14
+1,400% +$582 ﹤0.01% 2838
2024
Q4 		$42 Buy
+1
New +$50 ﹤0.01% 3674

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

SBI Securities's RARE Position: Q2 2026 in Review

SBI Securities reduced its Ultragenyx Pharmaceutical (RARE) stake by 34% in Q2 2026, selling an estimated $1.74K and leaving 133 shares worth $4.44K. The position accounts for ﹤0.01% of the portfolio, ranked #2226.

SBI Securities first reported a position in RARE in Q4 2024 and has held it in 7 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • SBI Securities held 133 shares of Ultragenyx Pharmaceutical worth $4.44K as of Q2 2026.
  • SBI Securities sold 70 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $1.74K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2226 holding.
  • SBI Securities first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and has held it in 7 quarters since.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.